Incyte Corporation (INCY) – What Are Researchers Saying About This Stock?

Shares of Incyte Corporation (NASDAQ:INCY) have earned an average recommendation of “Hold” from the twenty-five research firms that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, twelve have issued a hold rating and twelve have issued a buy rating on the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $131.43.

INCY has been the topic of a number of research analyst reports. Stifel Nicolaus boosted their price objective on shares of Incyte from $145.00 to $157.00 and gave the company a “buy” rating in a research report on Monday, October 5th. Royal Bank Of Canada raised their target price on shares of Incyte from $109.00 to $114.00 and gave the stock a “sector perform” rating in a research report on Thursday, October 8th. UBS Group reaffirmed a “neutral” rating and set a $127.00 target price on shares of Incyte in a research note on Monday, October 5th. Weiss Ratings cut shares of Incyte from a “buy (b+)” rating to a “buy (b)” rating in a research report on Friday, October 23rd. Finally, Benchmark reiterated a “buy” rating on shares of Incyte in a research report on Tuesday, October 13th.

Incyte Stock Performance

Shares of INCY stock opened at $116.80 on Friday. Incyte has a fifty-two week low of $89.25 and a fifty-two week high of $132.60. The firm has a market cap of $23.68 billion, a P/E ratio of 14.88, a P/E/G ratio of 4.83 and a beta of 0.74. The business’s 50 day moving average price is $120.62 and its 200-day moving average price is $108.07.

Incyte (NASDAQ:INCY) last announced its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported ($3.60) EPS for the quarter, topping analysts’ consensus estimates of ($3.93) by $0.33. Incyte had a return on equity of 29.93% and a net margin of 27.71%. The company had revenue of $1.56 billion during the quarter, compared to analyst estimates of $1.46 billion. During the same quarter last year, the firm posted $2.26 earnings per share. The firm’s revenue was up 14.0% on a year-over-year basis. As a group, equities analysts predict that Incyte will post 1.97 EPS for the current year.

Insider Transactions at Incyte

In other news, insider Pablo Cagnoni sold 10,801 shares of Incyte stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $125.56, for a total transaction of $1,356,173.56. Following the completion of the transaction, the insider directly owned 183,200 shares in the company, valued at approximately $23,002,592. This trade represents a 5.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 16.20% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Incyte

A number of hedge funds have recently added to or reduced their stakes in the company. Fiduciary Financial Advisors purchased a new position in Incyte in the 2nd quarter worth about $26,000. Continuum Advisory LLC purchased a new stake in shares of Incyte during the 2nd quarter valued at about $36,000. Latitude Advisors LLC purchased a new stake in shares of Incyte during the 3rd quarter valued at about $39,000. Quantbot Technologies LP bought a new stake in shares of Incyte in the second quarter worth approximately $52,000. Finally, Parkside Financial Bank & Trust grew its stake in shares of Incyte by 49.0% in the second quarter. Parkside Financial Bank & Trust now owns 727 shares of the biopharmaceutical company’s stock worth $82,000 after acquiring an additional 239 shares during the period. 96.97% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Incyte

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: Third-quarter revenue rose 14% year over year to $1.56 billion, exceeding the roughly $1.46 billion analyst estimate. The adjusted loss of $3.60 per share was also narrower than expected, reflecting solid underlying business performance. Incyte Reports Q3 Loss, Beats Revenue Estimates
• Positive Sentiment: Incyte raised its 2026 total net-sales guidance to $5.21 billion-$5.30 billion, from $5.13 billion-$5.26 billion previously. Opzelura guidance increased to $1.10 billion-$1.12 billion, supported by strong demand. Incyte Raises 2026 Sales Outlook
• Positive Sentiment: Key products performed well: Opzelura sales increased 36% to $255 million, Hematology and Oncology portfolio sales rose 38% to $235 million, and Jakafi and Jakafi XR sales grew 4% to $827 million. Incyte Third-Quarter Revenue and Guidance Update
• Positive Sentiment: Pipeline sentiment also improved after early data characterized Incyte’s G12D program as competitive in pancreatic cancer, while a partner began a Phase 1 study combining INCA33890 with another therapy in colorectal cancer. Incyte G12D Pipeline Update
• Neutral Sentiment: Management’s earnings call highlighted $3.9 billion in cash, cash equivalents and marketable securities at quarter-end, providing financial flexibility for development and acquisitions. Incyte Q3 Earnings Call Transcript
• Negative Sentiment: Incyte reported a GAAP net loss of approximately $785 million, or $3.86 per share, versus a profit in the prior-year quarter. The result was primarily driven by a $1.23 billion in-process research and development charge tied to the Vega Therapeutics acquisition. Incyte Q3 Loss and Vega Acquisition Charge
• Negative Sentiment: Although guidance was raised, some investors viewed the new full-year sales range as below the level implied by consensus expectations, limiting the positive reaction to the earnings beat.

Incyte Company Profile

Incyte Corporation is a biopharmaceutical company that discovers, develops and commercializes medicines for oncology and inflammatory or autoimmune diseases. The company focuses on therapies that target specific biological pathways, including Janus kinase (JAK), fibroblast growth factor receptor (FGFR) and other mechanisms involved in cancer and immune-related conditions.

Its key products include Jakafi (ruxolitinib), a JAK inhibitor used in the United States for certain blood cancers and graft-versus-host disease; Opzelura (ruxolitinib cream), a topical treatment for atopic dermatitis and nonsegmental vitiligo; and Pemazyre (pemigatinib), an FGFR inhibitor approved for selected patients with cholangiocarcinoma and certain myeloid or lymphoid neoplasms.